Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Supercharged unfolded proteins (SUPs) as potential topical drug delivery systems
Author Affiliations & Notes
  • Sven Schnichels
    University Eye Hospital Tübingen, Tübingen, Germany
  • Chiara Seiz
    University Eye Hospital Tübingen, Tübingen, Germany
  • Tina-Marie Thomas
    DWI-Leibniz-Institut fur Interaktive Materialien, Aachen, Nordrhein-Westfalen, Germany
  • Andreas Herrmann
    DWI-Leibniz-Institut fur Interaktive Materialien, Aachen, Nordrhein-Westfalen, Germany
  • José Hurst
    University Eye Hospital Tübingen, Tübingen, Germany
  • Footnotes
    Commercial Relationships   Sven Schnichels None; Chiara Seiz None; Tina-Marie Thomas None; Andreas Herrmann None; José Hurst None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3968. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sven Schnichels, Chiara Seiz, Tina-Marie Thomas, Andreas Herrmann, José Hurst; Supercharged unfolded proteins (SUPs) as potential topical drug delivery systems. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3968.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In topical treatment, only a few percent of the active ingredient reaches the inside of the eye. The reasons for this include washout through blinking, tear fluid, and the structural properties of the ocular surface. The same challenge also applies to dry eye disease for which long-lasting lubrication is needed. Supercharged unfolded polypeptides (SUPs) represent a possible solution for improved absorption, adhesion, and lubrication. SUPs have an elastin-like pentase sequence, which is positively overloaded with lysine at every 5th position. Electrostatic interaction with the negatively charged mucin layer of the cornea thus enables prolonged adhesion. In this project two different SUPs were tested for their potential as drug delivery systems.

Methods : The adhesion, penetration, and biocompatibility of the SUPs were tested ex vivo on porcine eyes and in vivo on rats. To this end, SUPs were applied to the corneas and incubated for different time points. The tear film was simulated in the pig eyes with a buffer solution. The localization and adhesion of the SUPs were evaluated histologically and via antibody staining against mucin-1 and galectin-3. The fluorescence signal of the SUPs was measured with a Fluorotron™ Master Fluorophotometer to quantitatively determine the adhesion time and penetration depth of the particles. To verify the high biocompatibility of the SUPs, cryosections were analyzed using TUNEL-staining and HE-staining. Lastly, specific adhesion to primary porcine corneal cells was evaluated compared to primary porcine Müller and the MIO-M1-cell line.

Results : The adhesion of the SUPs to the cornea of ex vivo porcine eyes was successfully demonstrated over 24 hours. The specific adhesion of SUPs to the mucin layer was confirmed by antibody staining against mucin-1 and galectin-3. Quantification by fluorophotometer showed that 96% of the two SUPs tested adhered to the cornea after 24 hours. Both SUPs showed no significant difference in adhesion. Moreover, excellent biocompatibility was shown. In vivo, the SUPs were still present on the corneal surface for up to four hours. In vitro studies with different cells (lines) proved specific adhesion to corneal cells.

Conclusions : The specific long-time adhesion of SUPs to the mucin layer of corneal epithelial cells was demonstrated. Thus, SUPs offer a promising approach as periocular drug carriers or/and for long-term lubrication in dry eye disease.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×